Recent Updates
Recently added Catalysts
LXRX

FDA Issues Complete Response Letter for Zynquista™ (sotagliflozin)

Friday, March 22, 2019 1 min read
Key Takeaway: FDA Issues Complete Response Letter for Zynquista™ (sotagliflozin)

Full Press Release Details

FDA Issues Complete Response Letter for Zynquista™ (sotagliflozin).
Tags: LXRX Viatris Investor Conferences Healthcare investor conferences healthcare conferences UBS Global Healthcare
Last updated: Mar 22, 2019